Core Viewpoint - Annovis Bio, Inc. has received a notice from the NYSE regarding non-compliance with continued listing standards due to its market capitalization and stockholders' equity falling below the required thresholds [1][2]. Company Financials - As of March 25, 2025, Annovis Bio's average market capitalization over a 30 trading-day period was approximately $37.9 million, which is below the $50 million requirement [2]. - The last reported stockholders' equity for the company as of December 31, 2024, was $9.3 million, also below the required $50 million [2]. Compliance Plan - The company plans to submit a compliance plan to the NYSE within 45 days of receiving the notice, detailing actions to regain compliance within 18 months [3]. - If the NYSE accepts the plan, the company's common stock will continue to be listed and traded, but will carry a ".BC" designation indicating non-compliance [4]. Impact on Operations - The notice does not affect the company's business operations or its reporting obligations with the SEC, nor does it trigger any default under material debt agreements [2]. - The common stock will continue to trade under the symbol "ANVS" during the compliance period, subject to adherence to the plan [4].
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE